The great clinical success of chimeric antigen receptor T cell (CAR-T) and PD-1/PDL-1 inhibitor
therapies suggests the drawing of a cancer immunotherapy age. However, a considerable proportion
of cancer patients currently receive little benefit from these treatment modalities, indicating that
multiple immunosuppressive mechanisms exist in the tumor microenvironment. In this review, we
mainly discuss recent advances in small molecular regulators targeting G Protein-Coupled Receptors
(GPCRs) that are associated with oncology immunomodulation, including chemokine receptors,
purinergic receptors, prostaglandin E receptor EP4 and opioid receptors. Moreover, we outline how they
affect tumor immunity and neoplasia by regulating immune cell recruitment and modulating tumor
stromal cell biology. We also summarize the data from recent clinical advances in small molecular regulators
targeting these GPCRs, in combination with immune checkpoints blockers, such as PD-1/PDL-1
and CTLA4 inhibitors, for cancer treatments.
Recent Advances in Cancer Research: Cell Biology, Molecular Biology, and Tumor Virology
